• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Biodesix Inc.

    5/30/25 4:10:49 PM ET
    $BDSX
    Medical Specialities
    Health Care
    Get the next $BDSX alert in real time by email
    S-8 1 d944169ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on May 30, 2025

    Registration No. 333-   

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Biodesix, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

     

    Delaware   20-3986492

    (State or Other Jurisdiction of

    Incorporation or Organization)

     

    (I.R.S. Employer

    Identification Number)

    919 W. Dillon Road

    Louisville, Colorado

      80027
    (Address of Principal Executive Offices)   (Zip Code)

    Biodesix, Inc. Employee Stock Purchase Plan

    (Full Title of the Plan)

    Scott Hutton

    President and Chief Executive Officer

    Biodesix, Inc.

    919 W. Dillon Road

    Louisville, Colorado 80027

    (303) 417-0500

    (Name, Address and Telephone Number, Including Area Code, of Agent for Service)

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     


    EXPLANATORY NOTE

    On April 15, 2025, the board of directors of Biodesix, Inc. (the “Registrant”) adopted, subject to stockholder approval, an amendment and restatement ( the “2025 Amendment and Restatement”) of the Biodesix, Inc. Employee Stock Purchase Plan (the “ESPP”), which increased the total number of shares of the Registrant’s common stock, par value $0.001 per share (the “Common Stock”) issuable under the ESPP by 1,451,500 shares of Common Stock. On May 20, 2025, at the Registrant’s 2025 annual meeting of stockholders (the “Annual Meeting”), a majority of the Registrant’s stockholders present in person or by proxy and entitled to vote on such matter at the Annual Meeting voted to approve the 2025 Amendment and Restatement, and the 2025 Amendment and Restatement became effective. This Registration Statement is being filed to register such additional 1,451,500 shares of Common Stock issuable under the ESPP.

    The shares of the Registrant’s Common Stock previously reserved for issuance under the ESPP were registered on the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission (the “Commission”) on November 2, 2020 (File No. 333-249805) (the “2020 Prior Form S-8”), the Registrant’s Registration Statement on Form S-8 filed with the Commission on February 2, 2023 (File No. 333-269536) (the “2023 Prior Form S-8”), the Registrant’s Registration Statement on Form S-8 filed with the Commission on February 2, 2024 (File No. 333-276842) (the “2024 Prior Form S-8”), and the Registrant’s Registration Statement on Form S-8 filed with the Commission on February 7, 2025 (File No. 333- 284767), (the “2025 Prior Form S-8”, together with the 2020 Prior Form S-8, the 2023 Prior Form S-8, and the 2024 Prior Form S-8, the “Prior Forms S-8”)

    This Registration Statement on Form S-8 relates to securities of the same class as that to which the Prior Forms S-8 relate, and is submitted in accordance with General Instruction E to Form S-8 regarding Registration of Additional Securities. Pursuant to General Instruction E of Form S-8, the contents of the Prior Forms S-8, to the extent relating to the registration of Common Stock issuable under the ESPP, are incorporated herein by reference and made part of this Registration Statement on Form S-8, except as modified or superseded hereby or by any subsequently filed document that is incorporated by reference herein or therein.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    ITEM 3.

    INCORPORATION OF DOCUMENTS BY REFERENCE

    The Registrant hereby incorporates by reference in this Registration Statement the following documents and information previously filed with the Commission (excluding any portions of such documents that have been “furnished” but not “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”):

     

      (1)

    The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on March 3, 2025, including all material incorporated by reference therein;

     

      (2)

    The Registrant’s Quarterly Report on Form 10-Q for the quarters ended March 31, 2025, filed with the Commission on May 13, 2025;

     

      (3)

    The Registrant’s Current Reports on Form 8-K, filed with the Commission on March  28, 2025, April  17, 2025 and May 21, 2025; and

     

      (4)

    The description of the Registrant’s Common Stock contained in the Registrant’s Registration Statement on Form 8-A filed with the Commission on October 26, 2020, pursuant to Section 12(b) of the Exchange Act, including any amendment or report for the purpose of updating such description.

    All documents subsequently filed by the Registrant with the Commission pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the respective dates of filing of such documents (such documents, and the documents enumerated above, being hereinafter referred to as “Incorporated Documents”).


    Any statement contained in an Incorporated Document shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed Incorporated Document modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    ITEM 8.

    EXHIBITS

     

    Exhibit
    No.

      

    Description

     4.1    Amended and Restated Certificate of Incorporation of Biodesix, Inc. (incorporated by reference to Exhibit 3.2 of the Registrant’s Registration Statement on Form S-1 (No. 333-249260), filed with the Commission on October 21, 2020).
     4.2    Amended and Restated Bylaws of Biodesix, Inc. (incorporated by reference to Exhibit 3.4 of the Registrant’s Registration Statement on Form S-1 (No. 333-249260), filed with the Commission on October 21, 2020).
     4.3    Biodesix, Inc. 2020 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.6 to the Company’s Registration Statement on Form S-1/A filed with the Commission on October 26, 2020).
     5.1*    Opinion of Sidley Austin LLP with respect to validity of issuance of securities.
    23.1*    Consent of Independent Registered Public Accounting Firm.
    23.2*    Consent of Sidley Austin LLP (included in Exhibit 5.1).
    24.1*    Power of Attorney (included on the signature page of the Registration Statement).
    107*    Filing Fee Exhibit.
     
    *

    Each document marked with an asterisk is filed herewith.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended (the “Securities Act”), the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Louisville, Colorado, on the 30th day of May, 2025.

     

    Biodesix, Inc.
    By:  

    /s/ Scott Hutton

      Scott Hutton
      President, Chief Executive Officer and Director
      (Principal Executive Officer)

    POWER OF ATTORNEY AND SIGNATURES

    Each of the undersigned officers and directors of Biodesix, Inc. does hereby severally constitute and appoint Scott Hutton and Robin Harper Cowie, and each of them acting alone, his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them for him or her and in his or her name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission and any applicable securities exchange or securities self-regulatory body, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his or her substitute or substitutes may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    SIGNATURE

      

    TITLE

     

    DATE

    /s/ Scott Hutton

    Scott Hutton

      

    President and Chief Executive Officer and Director

    (Principal Executive Officer)

      May 30, 2025

    /s/ Robin Harper Cowie

    Robin Harper Cowie

      

    Chief Financial Officer and Treasurer

    (Principal Financial Officer)

      May 30, 2025

    /s/ Christopher C. Vazquez

    Christopher C. Vazquez

      

    Chief Accounting Officer

    (Principal Accounting Officer)

      May 30, 2025

    /s/ John Patience

    John Patience

       Director   May 30, 2025

    /s/ Jean Franchi

    Jean Franchi

       Director   May 30, 2025

    /s/ Jon Faiz Kayyem

    Jon Faiz Kayyem, Ph.D.

       Director   May 30, 2025


    SIGNATURE

      

    TITLE

     

    DATE

    /s/ Lawrence T. Kennedy, Jr.

    Lawrence T. Kennedy, Jr.

       Director   May 30, 2025

    /s/ Hany Massarany

    Hany Massarany

       Director   May 30, 2025

    /s/ Matthew Strobeck

    Matthew Strobeck, Ph.D.

       Director   May 30, 2025
    Get the next $BDSX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BDSX

    DatePrice TargetRatingAnalyst
    5/14/2025Outperform → Mkt Perform
    William Blair
    9/16/2024Sector Outperform
    Scotiabank
    7/26/2024$3.00Buy
    Craig Hallum
    5/13/2024$2.80Buy
    TD Cowen
    5/3/2024$3.00Buy
    Lake Street
    11/17/2021$21.00 → $11.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $BDSX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chairman Patience John converted options into 22,874 shares, increasing direct ownership by 6% to 407,486 units (SEC Form 4)

      4 - BIODESIX INC (0001439725) (Issuer)

      7/2/25 4:33:08 PM ET
      $BDSX
      Medical Specialities
      Health Care
    • Director Massarany Hany converted options into 26,368 shares, increasing direct ownership by 9% to 310,135 units (SEC Form 4)

      4 - BIODESIX INC (0001439725) (Issuer)

      7/2/25 4:32:13 PM ET
      $BDSX
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Director Strobeck Matthew

      4 - BIODESIX INC (0001439725) (Issuer)

      5/22/25 4:16:43 PM ET
      $BDSX
      Medical Specialities
      Health Care

    $BDSX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Biodesix Partners with Association of Pulmonary Advanced Practice Providers (APAPP) to Deliver Nation's First Medical Education for APPs on Biomarkers in Lung Nodule and Lung Cancer Programs

      LOUISVILLE, Colo., June 10, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, announced today that it is partnering with the Association of Pulmonary Advanced Practice Providers (APAPP) to bring new educational programs aimed at their professional membership to better provide access and timely care to patients at risk for lung cancer. In this novel partnership, the two organizations will launch new educational resources for Lung Health providers on innovative lung nodule risk assessment testing, such as the Nodify Lung® blood-based tests, or cancer treatment decision support testing, such as the IQLung® blood-based tests. According to the Ame

      6/10/25 6:17:00 AM ET
      $BDSX
      Medical Specialities
      Health Care
    • Biodesix Announces New Data on the VeriStrat® Test to be Presented at the 2025 ASCO Annual Meeting

      LOUISVILLE, Colo., May 22, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, announced today that new data will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois at 2:30 pm ET on Saturday, May 31st. The presentation titled "Host immune classifier to predict survival with chemoimmunotherapy in PD-L1 ≥50% metastatic NSCLC" features data from the INSIGHT study (NCT03289780) which enrolled greater than 5,000 patients with non-small cell lung cancer (NSCLC). The data will be presented by Dr. Vamsidhar Velcheti, MD, Director of Thoracic Oncology at NYU Langone's Perlmutter Cancer Center. The Ver

      5/22/25 5:03:00 PM ET
      $BDSX
      Medical Specialities
      Health Care
    • Biodesix to Participate in Upcoming Investor Conferences

      LOUISVILLE, Colo., May 21, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced that members of the Biodesix management team, will participate in two upcoming investor conferences: 22nd Annual Craig-Hallum Institutional Investor Conference 1x1 MeetingsDate: Wednesday, May 28, 2025 Location: Minneapolis, MN 45th Annual William Blair Growth Stock Conference Presentation and 1x1 Meetings Date and Time: Wednesday, June 4, 2025 at 9:20 AM CTLocation: Chicago, IL The presentation will be webcast live and available for replay under "News & Events" in the Investors section of the Company's website at biodesix.com. About Biodesix Biodes

      5/21/25 6:00:00 AM ET
      $BDSX
      Medical Specialities
      Health Care

    $BDSX
    SEC Filings

    See more

    $BDSX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form S-8 filed by Biodesix Inc.

      S-8 - BIODESIX INC (0001439725) (Filer)

      5/30/25 4:10:49 PM ET
      $BDSX
      Medical Specialities
      Health Care
    • SEC Form 8-K filed by Biodesix Inc.

      8-K - BIODESIX INC (0001439725) (Filer)

      5/21/25 4:43:05 PM ET
      $BDSX
      Medical Specialities
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Biodesix Inc.

      SCHEDULE 13D/A - BIODESIX INC (0001439725) (Subject)

      5/20/25 4:11:48 PM ET
      $BDSX
      Medical Specialities
      Health Care
    • Director Schuler Jack W bought $1,316,624 worth of shares (4,723,239 units at $0.28) (SEC Form 4)

      4 - BIODESIX INC (0001439725) (Issuer)

      5/20/25 4:11:31 PM ET
      $BDSX
      Medical Specialities
      Health Care
    • Director Schuler Jack W bought $122,840 worth of shares (100,000 units at $1.23) (SEC Form 4)

      4 - BIODESIX INC (0001439725) (Issuer)

      11/22/24 12:30:34 PM ET
      $BDSX
      Medical Specialities
      Health Care
    • Director Kennedy Lawrence T. Jr bought $40,562 worth of shares (35,000 units at $1.16) (SEC Form 4)

      4 - BIODESIX INC (0001439725) (Issuer)

      11/22/24 12:30:13 PM ET
      $BDSX
      Medical Specialities
      Health Care

    $BDSX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Biodesix downgraded by William Blair

      William Blair downgraded Biodesix from Outperform to Mkt Perform

      5/14/25 8:54:25 AM ET
      $BDSX
      Medical Specialities
      Health Care
    • Scotiabank initiated coverage on Biodesix

      Scotiabank initiated coverage of Biodesix with a rating of Sector Outperform

      9/16/24 8:45:16 AM ET
      $BDSX
      Medical Specialities
      Health Care
    • Craig Hallum initiated coverage on Biodesix with a new price target

      Craig Hallum initiated coverage of Biodesix with a rating of Buy and set a new price target of $3.00

      7/26/24 7:48:11 AM ET
      $BDSX
      Medical Specialities
      Health Care

    $BDSX
    Leadership Updates

    Live Leadership Updates

    See more
    • Biodesix Announces Appointment of Lawrence (Lair) T. Kennedy, Jr. to Board of Directors

      Biodesix, Inc. (NASDAQ:BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the appointment of Lawrence (Lair) T. Kennedy, Jr. to the Company's Board of Directors (Board) and Audit Committee of the Board effective January 3, 2023. Mr. Kennedy brings to Biodesix more than 20 years of broad operating, corporate finance, company creation and investment experience with a specific focus in the healthcare industry. "We are delighted to welcome Lair to Biodesix's Board of Directors," said Scott Hutton, Chief Executive Officer of Biodesix. "He brings a wealth of business experience with a strong background in healthcare and diagnostics. We look fo

      12/16/22 4:01:00 PM ET
      $BDSX
      Medical Specialities
      Health Care
    • Biodesix Announces Appointment of Successful Innovator and Scientific Professional Jon Faiz Kayyem, PhD to Board of Directors

      Biodesix, Inc. (NASDAQ:BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced the appointment of Dr. Jon Faiz Kayyem to the company's board of directors. Dr. Kayyem's diverse career spans more than 20 years and includes experience in academia, lean startups, and Fortune 100 companies. He has served in various leadership positions throughout his career including numerous roles at GenMark Diagnostics, including Founder, CEO and President, Chief Scientific Officer, Senior Vice President of Research and Development. Prior to his work at GenMark Diagnostics, Dr. Kayyem served as Director and Founder of Calimmune and was Vice President of Life Sciences a

      12/8/21 6:00:00 AM ET
      $BDSX
      Medical Specialities
      Health Care

    $BDSX
    Financials

    Live finance-specific insights

    See more
    • Biodesix Announces First Quarter 2025 Results and Highlights

      Total Q1 2025 Revenue of $18.0 million, an increase of 21% over Q1 2024; Gross margins of 79.4% for Q1 2025; Q1 2025 Net loss improved by 18% compared to Q1 2024; Updated 2025 Revenue Guidance to a range of $80-85 million; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., May 13, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the first quarter ended March 31, 2025. "Our quarter was highlighted by continued progress toward our three key goals for 2025 – growing top line revenue, improving operational efficiencies and leverage, and advancing our pipeline," said Sc

      5/13/25 4:01:00 PM ET
      $BDSX
      Medical Specialities
      Health Care
    • Biodesix to Report First Quarter 2025 Financial Results on May 13, 2025

      LOUISVILLE, Colo., April 29, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the first quarter ended March 31, 2025 after the close of trading on Tuesday, May 13. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. Listeners can register for the webcast via this link. Analysts who wish to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the

      4/29/25 6:00:00 AM ET
      $BDSX
      Medical Specialities
      Health Care
    • Biodesix Announces Fourth Quarter and Fiscal Year 2024 Results

      Total Revenue of $71.3 million for FY2024, growing 45% over FY2023; Gross margins of 78% for FY2024, up 5% points over FY2023; FY2025 Total Revenue Guidance of $92-95 million; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., March 03, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the fourth quarter and year ended December 31, 2024 (fiscal 2024). "Biodesix concluded a strong 2024, advancing our key initiatives and delivering on our financial and operational goals," said Scott Hutton, Chief Executive Officer. "We exceeded our revenue targets, with total revenue re

      3/3/25 4:01:00 PM ET
      $BDSX
      Medical Specialities
      Health Care

    $BDSX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Biodesix Inc.

      SC 13G/A - BIODESIX INC (0001439725) (Subject)

      11/13/24 7:30:22 AM ET
      $BDSX
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Biodesix Inc.

      SC 13G - BIODESIX INC (0001439725) (Subject)

      6/24/24 12:16:38 PM ET
      $BDSX
      Medical Specialities
      Health Care
    • SEC Form SC 13D/A filed by Biodesix Inc. (Amendment)

      SC 13D/A - BIODESIX INC (0001439725) (Subject)

      5/23/24 7:10:37 PM ET
      $BDSX
      Medical Specialities
      Health Care